

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 August 2023 (24.08.2023)



(10) International Publication Number
WO 2023/159102 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)
A61K 35/768 (2015.01) C12N 7/00 (2006.01)
A61K 39/00 (2006.01)

(21) International Application Number:

PCT/US2023/062710

(22) International Filing Date:

16 February 2023 (16.02.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/268,139 17 February 2022 (17.02.2022) US
63/365,288 25 May 2022 (25.05.2022) US

(71) Applicants: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **VYRIAD, INC.** [US/US]; 2900


37th Street NW, Building 110, Rochester, Minnesota 55901 (US).

(72) Inventors: **GULLO, Giuseppe**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, New York 10591 (US). **RUSSELL, Stephen J.**; 2900 37th Street NW, Building 110, Rochester, Minnesota 55901 (US).

(74) Agent: **EL HIOUM, Dianna G.** et al.; Fox Rothschild LLP, 997 Lenox Drive, Lawrenceville, New Jersey 08648-2311 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG,

(54) Title: COMBINATIONS OF CHECKPOINT INHIBITORS AND ONCOLYTIC VIRUS FOR TREATING CANCER



* Flat dose of ipilimumab 50 mg is equivalent to 1 mg/kg Q6W

FIG. 1

(57) Abstract: The present disclosure relates to methods for inhibiting the growth of a tumor in a patient in need thereof. The methods comprise administering to the patient an oncolytic virus in combination with a therapeutically effective amount of a PD-1 inhibitor (e.g., cemiplimab or a bioequivalent thereof) and optionally, a therapeutically effective amount of a CTLA-4 inhibitor (e.g., ipilimumab or a bioequivalent thereof). In some embodiments, the administration of the combination results in enhanced tumor inhibition as compared to administration of either antibody or the virus alone. In some embodiments, the oncolytic virus is a recombinant vesicular stomatitis virus (VSV), such as VV1.

[Continued on next page]

WO 2023/159102 A1

NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,
RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))